ALK and anaplastic large cell lymphoma: Treatment with TYK2#1 for 72 h reduced cell viability by a mean of 73.4 ± 2.0% in the ALCL, ALK- cell lines Mac1, Mac2a, and FE-PD and 64.5 ± 2.7% in the ALCL, ALK+ cell lines Karpas-299, SR786, and SUDHL-1, whereas PBMCs from healthy donors were only slightly or not affected (Fig. 3b, Suppl.